Creative Medical Technology Holdings, Inc. — Cyborg Score 4/10
Mixed
Regenerative medicine and cell therapy
Strategic Profile
The Burn Pit Initiative is funded using existing partnerships (including Greenstone Biosciences), internal infrastructure, and prior vendor relationships to support AI-driven molecular modeling, iPSC development, and regenerative countermeasure work. CELZ-101 has received FDA Orphan Drug Designation for brittle Type 1 Diabetes, offering potential market exclusivity, with ongoing clinical trials in Type 1 Diabetes and chronic lower back pain representing multi-billion-dollar market opportunities. The company maintains a lean operational footprint with minimal dilution risk from near-term funding needs.
Cyborg Score Rationale
The company trades at a $7.87M market cap as of June 12, 2026, with significant stock price erosion (down 65.92% from its 52-week high). Analysts expect a final loss in 2027 before profitability in 2028, requiring an aggressive 56% average annual growth rate. However, regulatory approvals and orphan drug designation provide validation pathways.
Top Insights
(January 2026) BioDefense Burn Pit Initiative received regulatory approval with zero additional fundraising required, reducing shareholder dilution
(June 2026) Market cap deteriorated to $7.87M despite clinical progress, signaling investor skepticism or capital constraints
FDA Orphan Drug Designation for CELZ-101 in brittle Type 1 Diabetes provides regulatory exclusivity pathway and smaller addressable market focus
AI-driven molecular modeling and iPSC platform provide potential differentiation, but commercialization timeline remains uncertain